CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

  • Authors:
    • Milan Reinis
    • Jana Símová
    • Marie Indrová
    • Jana Bieblová
    • Jan Bubeník
  • View Affiliations

  • Published online on: May 1, 2007     https://doi.org/10.3892/ijo.30.5.1247
  • Pages: 1247-1251
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC class I-positive and -deficient tumours after debulking the tumour mass by chemotherapy or surgery. We employed an animal model resembling human papillomavirus (HPV) 16-associated tumours. Tumour cell lines with distinct cell surface expression of the MHC class I molecules were injected into syngeneic C57BL/6 mice, and the growing tumours were either subjected to cytoreductive chemotherapy with ifosfamide derivative, CBM-4A, or surgically removed. Subsequent treatment with synthetic CpG ODN significantly blocked the growth of the recurrent tumours. Our results indicate that the therapy with CpG ODN can be effective for the treatment of minimal residual tumour disease of the tumours that have escaped from the immune surveillance by downmodulating the MHC class I expression.

Related Articles

Journal Cover

May 2007
Volume 30 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Reinis M, Símová J, Indrová M, Bieblová J and Bubeník J: CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int J Oncol 30: 1247-1251, 2007
APA
Reinis, M., Símová, J., Indrová, M., Bieblová, J., & Bubeník, J. (2007). CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. International Journal of Oncology, 30, 1247-1251. https://doi.org/10.3892/ijo.30.5.1247
MLA
Reinis, M., Símová, J., Indrová, M., Bieblová, J., Bubeník, J."CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours". International Journal of Oncology 30.5 (2007): 1247-1251.
Chicago
Reinis, M., Símová, J., Indrová, M., Bieblová, J., Bubeník, J."CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours". International Journal of Oncology 30, no. 5 (2007): 1247-1251. https://doi.org/10.3892/ijo.30.5.1247